
美国食品药品监管机构加大了对印度制药设施的突击审计力度,强化了对出口全球最大仿制药市场产品的监管。
The US food and drug regulator has increased surprise audits at Indian pharmaceutical facilities, stepping up oversight of exports to the world’s largest market for generics.
“重要的一点是,我们现在正在开展不通知检查,”美国食品药品监督管理局(FDA)国际关系专家尼尔·邦扎尼在孟买举行的一场活动上表示。“过去,检查必须通过我们的当地对口部门或公共卫生机构进行协调。现在这些检查都是不通知的。”监管专业人士协会(RAPS)本月援引FDA检查与调查办公室副专员伊丽莎白·米勒的数据报道称,在截至3月31日的财政年度中,FDA在印度进行的87%审计均为无预先通知,高于前12个月的47%。
“One of the important things is that we are now conducting unannounced inspections,” Neil Bonzagni, an international relations specialist at the US Food and Drug Administration, said at an event in Mumbai. “Previously, an inspection had to be coordinated through our local counterparts or public health authorities. Now those are unannounced.”The regulator conducted 87% of its audits in India without prior intimation in the fiscal year ended March 31, up from 47% in the previous 12 months, the Regulatory Affairs Professionals Society reported this month, citing Elizabeth Miller, associate commissioner at the FDA’s office of inspections and investigations.
印度拥有美国境外数量最多的FDA认证设施,供应美国市场销售的所有仿制药中约40%。更严格的质量检查正值该国旨在进一步提振药品出口之际。
India is home to the highest number of FDA-approved facilities outside the US, supplying about 40% of all generic medicines sold in the American market. Stricter quality checks are coming just as the country aims to further boost drug exports.
这个自称“世界药房”的南亚国家,因出口药品在2022年和2023年与死亡病例有关联,而面临质量担忧。数十名冈比亚和乌兹别克斯坦儿童在服用印度生产的非处方止咳糖浆后死亡。四名美国人在使用受细菌污染的眼药水后死亡,该眼药水同样源自印度出口。
The South Asian nation, which calls itself the “pharmacy to the world,” has faced quality concerns after exported drugs were linked to deaths in 2022 and 2023. Dozens of children died in Gambia and Uzbekistan after consuming over-the-counter cough syrups made in India. Four Americans died after using bacteria-laced eyedrops, also shipped from India.
Bonzagni 表示,FDA 倾向于从“摇篮到坟墓”评估供应链,包括原材料、制造工艺和成品分销。“无通知检查确实有助于我们确保那里的安全。”他还表示,随着印度企业加大对这一药品类别的关注,包括抗肥胖疗法,监管机构明年 5 月还将在新德里和海得拉巴举办路演,讨论生物类似药。印度是首个获得诺和诺德减重药物仿制药的大型市场,随着该公司专利在其他国家到期,当地竞争对手正准备在全球范围内供应这些药物。
The FDA likes to assess the supply chain “from cradle to grave,” including raw materials, manufacturing processes, and distribution of finished product, Bonzagni said. “The unannounced inspections really do help us ensure safety there.”The regulator will also conduct road shows to discuss biosimilars in May next year in New Delhi and Hyderabad, he said, as Indian companies increase focus on this category of drugs, including anti-obesity therapies. India is the first large market to get generic copies of Novo Nordisk’s weight-loss drugs, with local rivals preparing to supply them globally as the company’s patents expire in other countries.